Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC).

[1]  Gen Sheng Wu.  TRAIL as a target in anti-cancer therapy. , 2009, Cancer letters.

[2]  E. Dirice,et al.  Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. , 2009, Human gene therapy.

[3]  S. de Jong,et al.  TRAIL receptor signalling and modulation: Are we on the right TRAIL? , 2009, Cancer treatment reviews.

[4]  E. Dirice,et al.  High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients , 2009, Pancreas.

[5]  L. Norian,et al.  TRAIL gene therapy: from preclinical development to clinical application. , 2009, Current gene therapy.

[6]  S. Wang,et al.  The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway , 2008, Oncogene.

[7]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Thornhill,et al.  Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers. , 2008, Oral oncology.

[9]  E. Dirice,et al.  Molecular mechanisms of death ligand‐mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes , 2008, Journal of cellular biochemistry.

[10]  E. Dirice,et al.  High Levels of Endogenous Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression Correlate With Increased Cell Death in Human Pancreas , 2008, Pancreas.

[11]  T. Griffith,et al.  Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. , 2008, Urologic oncology.

[12]  Shi-Yong Sun,et al.  Modulation of death receptors by cancer therapeutic agents , 2008, Cancer biology & therapy.

[13]  T. Griffith,et al.  DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells , 2007, Cancer Gene Therapy.

[14]  T. Griffith,et al.  TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[15]  Jean Wu,et al.  Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression , 2007, BMC Cancer.

[16]  E. Terzioğlu,et al.  Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. , 2007, Rheumatology.

[17]  C. Akdis,et al.  Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. , 2006, Human gene therapy.

[18]  Xiangwei Wu,et al.  Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. , 2006, Cancer biology & therapy.

[19]  B. Sipos,et al.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.

[20]  E. Dirice,et al.  Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells , 2005, BMC Cancer.

[21]  J. Martignetti,et al.  A study of TRAIL receptors in squamous cell carcinoma of the head and neck. , 2005, Archives of otolaryngology--head & neck surgery.

[22]  D. Metzger,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and CD56 Expression in Patients With Type 1 Diabetes Mellitus , 2005, Pancreas.

[23]  G. Almadori,et al.  Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review. , 2004, European journal of cancer.

[24]  P. Parsons,et al.  Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. , 2004, British journal of plastic surgery.

[25]  T. Griffith,et al.  Inhibition of the NF-κB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells , 2004, Cancer Gene Therapy.

[26]  I. Fleming,et al.  AJCC/TNM cancer staging, present and future , 2001, Journal of surgical oncology.

[27]  T. Rebbeck,et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Jen,et al.  Rare loss-of-function mutation of a death receptor gene in head and neck cancer. , 1998, Cancer research.

[29]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[30]  C. Hao,et al.  TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. , 2009, Reviews on recent clinical trials.

[31]  C. Xie,et al.  Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells. , 2009, Oncology reports.

[32]  G. Luleci,et al.  Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. , 2007, The Journal of urology.

[33]  G. Luleci,et al.  Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. , 2006, Cancer gene therapy.

[34]  G. Luleci,et al.  Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma , 2003 .